...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of women’s health >Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women.
【24h】

Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women.

机译：评估围绝经期和绝经后妇女非激素治疗血管舒缩症状的风险和益处。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Vasomotor symptoms (VMS); (hot flushes and night sweats) are the most common menopausal complaint for which women seek treatment. Several therapies can be considered to help manage these complaints. The objective of this review is to assess the risks and benefits of available and emerging therapeutic options for the management of menopausal VMS. METHODS: A review of the literature was conducted based on relevant publications identified through a PubMed search for clinical trials of agents used in the treatment of VMS. RESULTS: Hormone therapy (HT) remains the most effective treatment available, but there will always remain a need for nonhormonal options. Evidence does not support the efficacy of alternative or over-the-counter products, such as phytoestrogens and black cohosh, and their long-term safety is largely unknown. There is evidence supporting the efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the management of VMS from clinical trials of paroxetine, venlafaxine, and desvenlafaxine. Gabapentin appears to be effective, but the doses required may cause poor tolerability and reduced patient adherence. Data also suggest that clonidine has a modest effect at the expense of considerable adverse effects. CONCLUSIONS: Choosing an appropriate treatment approach for the management of VMS requires careful assessment of the riskbenefit ratio of each alternative, as well as individual patient preference.
机译：背景：血管舒缩症状（VMS）; （潮热和盗汗）是妇女寻求治疗的最常见的绝经期症状。可以考虑几种疗法来帮助处理这些不适。这项审查的目的是评估更年期VMS管理的可用和新兴治疗方案的风险和收益。方法：根据相关出版物对文献进行回顾，这些出版物是通过PubMed搜索来确定用于治疗VMS的药物的临床试验而确定的。结果：激素治疗（HT）仍然是最有效的治疗方法，但始终需要非激素治疗。证据不支持替代性或非处方产品（例如植物雌激素和黑升麻）的功效，其长期安全性在很大程度上尚不清楚。帕罗西汀，文拉法辛和去甲文拉法辛的临床试验表明，有证据支持选择性5-羟色胺再摄取抑制剂（SSRIs）和5-羟色胺去甲肾上腺素再摄取抑制剂（SNRIs）对VMS的管理功效。加巴喷丁似乎有效，但所需剂量可能导致耐受性差和患者依从性下降。数据还表明可乐定以适度的作用为代价，但以相当大的不利作用为代价。结论：选择合适的治疗方法来管理VMS需要仔细评估每个替代方案的风险收益率以及患者的个人偏好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号